FDA panel considers loosening regulations on certain unapproved peptides
The Food and Drug Administration advisory panel is holding a second day of meetings on whether to loosen restrictions on certain unapproved peptide drugs.
The panel voted Thursday to broaden access to four peptides.
KFF Health News' Amy Maxmen has more. ...
이 뉴스, 어떠셨어요?
탭 한 번으로 반응 · 로그인 불필요
공식 발표 ↔ 진영별 보도
FDA panel considers loosening regulations on certain unapproved peptides
Inside the unconventional FDA panel that could reshape the peptide industry
What to Know About Peptides the FDA Is Considering for Use
FDA advisory panel recommends loosening restrictions on 2 unapproved peptides
+4
FDA panel overrules its own scientists to ease access to unproven peptide injections
STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
US panel backs trendy peptides despite safety concerns
WATCH LIVE: Day 2 of FDA advisory panel meeting to consider use of peptides
+5
La nueva batalla de los péptidos: la FDA revisa las sustancias promocionadas en redes sociales mientras sus científicos cuestionan su eficacia
US panel backs trendy peptides despite safety concerns
FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers